- CEO
- Zheng Sun
- Full Time Employees
- 3
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 175 Pearl Street Brooklyn NY United States of America 11201
- IPO Date
- Jul 25, 2024
- Business
- DT Cloud Star Acquisition Corporation is a blank check company, or special purpose acquisition company (SPAC), incorporated in the Cayman Islands in 2022 and headquartered in Brooklyn, New York; it focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities, without current operations or revenues, and targets industries complementary to its management team's expertise in cross-border mergers, acquisitions, and capital markets, including high-growth opportunities with compelling economics, recurring revenue potential, defensible market positions, and strong management seeking public market access. Its core offerings consist solely of its public securities traded on Nasdaq under tickers DTSQ (ordinary shares), DTSQU (units comprising one ordinary share and one right to receive one-ninth of one ordinary share upon a business combination), and DTSQR (rights); each unit was initially offered at $10.00 during its July 2024 initial public offering, which raised $69 million including the full exercise of the underwriters' over-allotment option for 900,000 units. Geographically, the company operates primarily in the United States with a management team led by CEO Zheng Sun and CFO Kenneth Lam, supported by a sponsor DT Cloud Star Management Limited. Recent developments include the completion of its upsized IPO in July 2024; multiple extensions of its business combination deadline, most recently to November 26, 2025 via shareholder approval in October 2025 with a $75,000 monthly deposit and proposals to further extend to October 2026 while reducing extension fees to nil; entry into non-redemption agreements with certain shareholders in October 2025; election of directors including Sam Zheng Sun, Kenneth Lam, Shaoke Li, Longjiao Li, and Chi Zhang at its 2025 annual meeting; and the appointment of Dr. Xunyong Zhou, a biotechnology expert with over 20 patents and leadership in health technology ventures, as a director on November 26, 2025, signaling potential interest in healthcare or biotech sectors.